Key Insights Insiders appear to have a vested interest in Pulse Biosciences' growth, as seen by their sizeable...
Even if it's not a huge purchase, we think it was good to see that Burke Barrett, the President & CEO of Pulse...
HAYWARD, Calif., May 20, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock